```
     FILE 'REGISTRY' ENTERED AT 12:52:54 ON 29 DEC 2009
L1              STRUCTURE UPLOADED
L2            1 S L1
L3            1 S L1 FAM FULL

     FILE 'HCAPLUS' ENTERED AT 12:53:33 ON 29 DEC 2009
L4            7 S L3
```

```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 12:52:54 ON 29 DEC 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   28 DEC 2009  HIGHEST RN 1198837-82-9
DICTIONARY FILE UPDATES:  28 DEC 2009  HIGHEST RN 1198837-82-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10529431claim17.str
```



```
chain nodes :
21  22  23  29  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52

ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  24  25  26
27  28  30  31  32  33  34  35
chain bonds :
2-21  8-47  9-46  10-45  11-38  12-40  13-15  16-39  17-41  18-42  19-43  20-44
21-22  21-23  23-24  25-48  27-49  28-29  29-30  31-50  32-51  33-36  34-37  35-52
```

```
ring bonds :
1-2  1-7  2-3  3-4  3-8  4-5  4-11  5-6  6-7  6-12  7-14  8-9  9-10  10-11  12-13
13-14  15-16  15-20  16-17  17-18  18-19  19-20  24-25  24-28  25-26  26-27  27-28
30-31  30-35
31-32  32-33  33-34  34-35
exact/norm bonds :
1-2  1-7  2-3  2-21  4-5  5-6  6-7  6-12  7-14  12-13  13-14  21-22  24-25  24-28
25-26  26-27  27-28
exact bonds :
8-47  9-46  10-45  11-38  12-40  13-15  16-39  17-41  18-42  19-43  20-44  21-23
23-24  25-48  27-49  28-29  29-30  31-50  32-51  33-36  34-37  35-52
normalized bonds :
3-4  3-8  4-11  8-9  9-10  10-11  15-16  15-20  16-17  17-18  18-19  19-20  30-31
30-35  31-32  32-33  33-34  34-35


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:CLASS
22:CLASS  23:CLASS  24:Atom  25:Atom  26:Atom  27:Atom  28:Atom  29:CLASS  30:Atom
31:Atom  32:Atom
33:Atom  34:Atom  35:Atom  36:CLASS  37:CLASS  38:CLASS  39:CLASS  40:CLASS
41:CLASS  42:CLASS
43:CLASS  44:CLASS  45:CLASS  46:CLASS  47:CLASS  48:CLASS  49:CLASS  50:CLASS
51:CLASS  52:CLASS




L1      STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 12:53:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        2 TO ITERATE

100.0% PROCESSED        2 ITERATIONS                                 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            2 TO      124
PROJECTED ANSWERS:               1 TO       80

L2            1 SEA SSS SAM L1

=> d l1 scan
L1 HAS NO ANSWERS


=> d l2 scan

L2   1 ANSWERS   REGISTRY  COPYRIGHT 2009 ACS on STN
IN   Benzonitrile, 4-[[5-[2-[2-(2-bromophenyl)-6-fluoro-5H-imidazo[2,1-
     c][1,4]benzodiazepin-10(11H)-yl]-2-oxoethyl]-1H-imidazol-1-yl]methyl]-2-
     methoxy-
MF   C31 H24 Br F N6 O2
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 fam full
FULL SEARCH INITIATED 12:53:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L3 1 SEA FAM FUL L1

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	73.33	73.55

FILE 'HCAPLUS' ENTERED AT 12:53:33 ON 29 DEC 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 29 Dec 2009 VOL 152 ISS 1
FILE LAST UPDATED: 28 Dec 2009 (20091228/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 7 L3

=> d l4 1-7 ti abs bib

L4 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of imidazopyrazines, imidazobenzodiazepines, and related compounds as prenyl transferase inhibitors.
GI



I

AB Title compds. [I; X = (CHR11)n3(CH2)n4Z(CH2)n5; n3 = 0, 1; n4, n5 = 0-3; Z = O, bond, etc.; Y = CO, CH2, CS, bond; R1 = (substituted) imidazolyl, triazolyl, etc.; R3 = H, (substituted) alkyl, alkenyl, etc.; R4, R5 = H, (substituted) alkyl, cycloalkyl, etc.; R6 = H, (substituted) alkyl, alkenyl, etc.; R7 = H, :O, :S, (substituted) alkyl, etc.; W = null, C], were prepared as prenyl transferase inhibitors (no data). Thus, 1-(2-ethoxy-2-oxoethyl)-2-[(1S)-[[(phenylmethoxy)carbonyl]amino]pentyl]-4-(2-methoxyphenyl)imidazole (preparation given) was hydrogenated in HOAc over Pd/C to give 8-butyl-6-oxo-2-(2-methoxyphenyl)imidazo[1,2-a]pyrazine. This was converted to 8-butyl-7-[3-(imidazol-5-yl)-1-oxopropyl]-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine in several steps.
AN 2008:490553 HCAPLUS <<LOGINID::20091229>>
DN 148:449668
TI Preparation of imidazopyrazines, imidazobenzodiazepines, and related compounds as prenyl transferase inhibitors.
IN Gordon, Thomas D.; Morgan, Barry A.
PA Societe de Conseils de Recherches et d'Applications Scientifiques, S.a.S., Fr.
SO U.S., 34pp., Cont.-in-part of U.S. Ser. No. 224428.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 7361656	B2	20080422	US 2006-353518	20060214

```
     US 20060142275        A1    20060629
     WO 2000039130         A2    20000706    WO 1999-US31302        19991230
     WO 2000039130         A3    20001102
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
             MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
             SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     EP 1382607            A2    20040121    EP 2003-78315          19991230
     EP 1382607            A3    20040630
     EP 1382607            B1    20090819
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI, CY
     US 7084135            B1    20060801    US 2001-868356         20010810
     US 20080176835        A1    20080724    US 2007-929118         20071030
PRAI US 1998-114301P       P     19981231
     US 1998-224428        B2    19981231
     WO 1999-US31302       W     19991230
     US 2001-868356        A1    20010810
     EP 1999-968984        A3    19991230
     US 2006-353518        A3    20060214
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS   MARPAT 148:449668
RE.CNT  7     THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4   ANSWER 2 OF 7  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Preparation of imidazopyrazines, imidazobenzodiazepines, and related
     compounds as prenyl transferase inhibitors
GI
```



I

AB Title compds. [I; X = (CHR11)n3(CH2)n4Z(CH2)n5; n3 = 0, 1; n4, n5 = 0-3; Z = O, NR12, S, bond; Y = CO, CH2, CS, bond; R1 = (substituted) imidazolyl, triazolyl, tetrazolyl, benzimidazolyl, isoquinolinyl, pyridyl, etc.; R3 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R4, R5 = H, (substituted) alkyl, cycloalkyl, aryl, heterocyclyl; R6 = H, (substituted) alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R7 = H, :O, :S, (substituted) alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; W = null, C], were prepared as prenyl transferase inhibitors (no data). Thus, 1-(2-ethoxy-2-oxoethyl)-2-[(1S)-[[(phenylmethoxy)carbonyl]amino]pentyl]-4-(2-methoxyphenyl)imidazole (preparation given) was hydrogenated in HOAc over

Pd/C to give 8-butyl-6-oxo-2-(2-methoxyphenyl)imidazo[1,2-a]pyrazine. This was converted to 8-butyl-7-[3-(imidazol-5-yl)-1-oxopropyl]-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine in several steps. Pharmaceutical composition comprising the compound I and methods of treating cancer and other diseases are disclosed.

AN 2006:759518 HCAPLUS <<LOGINID::20091229>>

DN 145:188920

TI Preparation of imidazopyrazines, imidazobenzodiazepines, and related compounds as prenyl transferase inhibitors

IN Gordon, Thomas D.; Morgan, Barry A.

PA Societe De Conseils De Recherches Et D'Applications Scientifiques, Sas, Fr.

SO U.S., 37 pp., Cont.-in-part of U.S. Ser. No. 224,428, abandoned.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 7084135	B1	20060801	US 2001-868356	20010810
	WO 2000039130	A2	20000706	WO 1999-US31302	19991230
	WO 2000039130	A3	20001102		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1382607	A2	20040121	EP 2003-78315	19991230
	EP 1382607	A3	20040630		
	EP 1382607	B1	20090819		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	US 7361656	B2	20080422	US 2006-353518	20060214
	US 20060142275	A1	20060629		
	US 20080176835	A1	20080724	US 2007-929118	20071030
PRAI	US 1998-114301P	P	19981231		
	US 1998-224428	B2	19981231		
	WO 1999-US31302	W	19991230		
	EP 1999-968984	A3	19991230		
	US 2001-868356	A1	20010810		
	US 2006-353518	A3	20060214		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 145:188920

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Compositions containing farnesyl transferase inhibitors for the treatment of nasopharyngeal carcinoma

GI



I

AB Disclosed is a novel drug combination which is useful for the treatment of nasopharyngeal carcinoma, said novel drug combination comprising one or more of a farnesyl transferase inhibitor (FTI) and one or more of an anthracycline. An example FTI is I. Examples were given for assessment of farnesyl transferase inhibition in intact cells and cleavage of TRAF1 in C15 cells treated with a FTI and doxorubicin combination.

AN 2004:291952 HCAPLUS <<LOGINID::20091229>>
DN 140:315043

TI Compositions containing farnesyl transferase inhibitors for the treatment of nasopharyngeal carcinoma

IN Prevost, Gregoire; Busson, Pierre; Vicat, Jean-Michel
PA Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S., Fr.; Centre National De Recherche Scientifique

SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004028541	A2	20040408	WO 2003-IB4922	20030929
	WO 2004028541	A3	20040701		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003274565	A1	20040419	AU 2003-274565	20030929
	EP 1542691	A2	20050622	EP 2003-758540	20030929
	EP 1542691	B1	20090107		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006500421	T	20060105	JP 2004-539385	20030929
	AT 419852	T	20090115	AT 2003-758540	20030929
	ES 2316811	T3	20090416	ES 2003-758540	20030929
	US 20060166907	A1	20060727	US 2005-529431	20050325
	US 20080161253	A1	20080703	US 2008-74729	20080306
PRAI	US 2002-414103P	P	20020927		
	WO 2003-IB4922	W	20030929		
	US 2005-529431	A1	20050325		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 140:315043

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive nasopharyngeal carcinoma cells treated with doxorubicin combined with a farnesyl-transferase inhibitor
AB Epstein-Barr virus (EBV)-associated nasopharyngeal carcinomas (NPC) are much more sensitive to chemotherapy than other head and neck carcinomas. Spectacular regressions are frequently observed after induction chemotherapy. However, these favorable responses are difficult to predict and often of short duration. So far there have been only few expts. to investigate the mechanisms which underline the cytotoxic effects of anti-neoplastic drugs against NPC cells. In addition, these studies were performed almost entirely on EBV-neg. cell lines therefore not truly representative of NPC cells. For the first time, we have used two EBV-pos. NPC tumor lines derived from a North African (C15) and a Chinese (C666-1) patient as in vitro targets for a panel of anti-neoplastic agents. Doxorubicin, taxol and in a lesser extent cis-platinum efficiently inhibited NPC cell proliferation at clin. relevant concns., but all three agents failed to induce apoptosis. However, massive apoptosis of C15 cells was achieved when doxorubicin (1 μM) was combined with a farnesyl-transferase inhibitor, BIM 2001 (5 μM). Moreover, this apoptotic process was associated with a caspase-dependent early cleavage of the TNF-receptor associated factor 1 (TRAF-1) mol., a signaling adaptor which is specifically expressed in latently EBV-infected cells. TRAF-1 cleavage might become a useful indicator of chemo-induced apoptosis in EBV-associated NPCs.
AN 2003:28618 HCAPLUS <<LOGINID::20091229>>
DN 139:46523
TI Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive nasopharyngeal carcinoma cells treated with doxorubicin combined with a farnesyl-transferase inhibitor
AU Vicat, Jean-Michel; Ardila-Osorio, Hector; Khabir, Abdelmajid; Brezak, Marie-Christine; Viossat, Isabelle; Kasprzyk, Philip; Jlidi, Rachid; Opolon, Paule; Ooka, Tadamassa; Prevost, Gregoire; Huang, Dolly P.; Busson, Pierre
CS UMR 1598, Institut Gustave Roussy, Villejuif, 94805, Fr.
SO Biochemical Pharmacology (2003), 65(3), 423-433
CODEN: BCPCA6; ISSN: 0006-2952
PB Elsevier Science Inc.
DT Journal
LA English
OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of pharmaceutical compositions containing mikanolide, dihydromikanolide or an analog thereof combined with another anticancer agent for therapeutic use in cancer treatment
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention concerns a product comprising at least mikanolide (I), dihydromikanolide or an analog, e.g., II [R1 = H, SR4, NR4R5; R2 = SR6, NR6R7; R3 = OH, O-acyl, O-silyl, O-carbamyl; R4, R6 = alkyl, cycloalkyl, (cycloalkyl)alkyl, hydroxyalkyl, (un)substituted aryl, aralkyl; R5, R7 =

H, alkyl, cycloalkyl, (cycloalkyl)alkyl, hydroxyalkyl, (un)substituted aryl, aralkyl; R4R5 = 5- to 7-membered N-containing ring] and III, or their pharmaceutically acceptable salts, combined with at least one other anticancer agent for simultaneous, sep. or prolonged therapeutic use in cancer treatment. In a preferred embodiment of the invention, the mikanolide, dihydromikanolide or one analog thereof is combined with enzymic inhibitors such as G heterotrimeric protein inhibitors, IV [X = R22; Y = R18; XY = 6-membered ring, CHR18CHR19; R11 = H, lower alkyl, alkylthio; R12, R13 = H, lower alkyl; R14 = O, H2; R5 = H, lower alkyl, (cycloalkyl)alkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl; R16, R17 = H, CONHCHR13CO2R14, lower alkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl; R18, R19 = H, lower alkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl; R18R19 = aryl or heterocycly ring; R20, R21 = H, aryl, heterocyclyl, alkyl, arylalkyl, heterocyclylalkyl; R22 = NR9, S, O; R23 = ; R24 = H, lower alkyl], V (R18, R19 = H, lower alkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl; R18R19 = aryl or heterocycly ring) or VI (R22 = NR9, S, O), or alkylating agents such as cis-platin. Thus, VII was prepared from mikanolide. VII was tested for cell proliferation inhibition activity [only 34% of cells lived when combined with VIII·HCl (vs. human colon cancer HT-29 cells)].

AN 2002:927175 HCAPLUS <<LOGINID::20091229>>

DN 138:14131

TI Preparation of pharmaceutical compositions containing mikanolide, dihydromikanolide or an analog thereof combined with another anticancer agent for therapeutic use in cancer treatment

IN Prevost, Gregoire; Coulomb, Helene; Lavergne, Olivier; Lanco, Christophe; Teng, Beng-Poon

PA Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Fr.

SO PCT Int. Appl., 103 pp.
CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096348	A2	20021205	WO 2002-FR1800	20020529
	WO 2002096348	A3	20040506		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	FR 2825278	A1	20021206	FR 2001-7104	20010530
	CA 2448528	A1	20021205	CA 2002-2448528	20020529
	AU 2002313087	A1	20021209	AU 2002-313087	20020529
	EP 1438039	A2	20040721	EP 2002-738284	20020529
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004533456	T	20041104	JP 2002-592861	20020529
	CN 1691941	A	20051102	CN 2002-812592	20020529
	HU 2004000153	A2	20070730	HU 2004-153	20020529
	US 20040138245	A1	20040715	US 2003-478387	20031211
PRAI	FR 2001-7104	A	20010530		
	WO 2002-FR1800	W	20020529		

OS MARPAT 138:14131

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Product inhibiting heterotrimeric G protein signal transduction combined with another anticancer agent for therapeutic use in cancer treatment
AB The invention provides a product inhibiting heterotrimeric G protein signal transduction combined with another anticancer agent, in particular a farnesyltransferase inhibitor, taxol or gemcitabine, for simultaneous, sep., or prolonged therapeutic use in cancer treatment.
AN 2001:359845 HCAPLUS <<LOGINID::20091229>>
DN 134:361346
TI Product inhibiting heterotrimeric G protein signal transduction combined with another anticancer agent for therapeutic use in cancer treatment
IN Prevost, Gregoire; Lonchampt, Marie-Odile; Gordon, Thomas; Morgan, Barry
PA Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.), Fr.
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001034203	A1	20010517	WO 2000-FR3098	20001108
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2800616	A1	20010511	FR 1999-14037	19991109
	FR 2800616	B1	20020118		
	FR 2803524	A1	20010713	FR 2000-104	20000106
	FR 2803524	B1	20020419		
	CA 2390317	A1	20010517	CA 2000-2390317	20001108
	EP 1233787	A1	20020828	EP 2000-976116	20001108
	EP 1233787	B1	20041208		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	HU 2002003241	A2	20030228	HU 2002-3241	20001108
	HU 2002003241	A3	20060728		
	JP 2003513940	T	20030415	JP 2001-536200	20001108
	EP 1430934	A1	20040623	EP 2004-75491	20001108
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	AT 284224	T	20041215	AT 2000-976116	20001108
	PT 1233787	E	20050429	PT 2000-976116	20001108
	ES 2234692	T3	20050701	ES 2000-976116	20001108
	RU 2298417	C2	20070510	RU 2002-115262	20001108
	US 7034024	B1	20060425	US 2002-129569	20020621
	US 20060074078	A1	20060406	US 2005-272304	20051110
	US 20090270341	A1	20091029	US 2009-496896	20090702
PRAI	FR 1999-14037	A	19991109		
	FR 2000-104	A	20000106		
	EP 2000-976116	A3	20001108		
	WO 2000-FR3098	W	20001108		

US 2002-129569 A3 20020621
US 2005-272304 B3 20051110
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 134:361346
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of imidazopyrazines, imidazobenzodiazepines, and related compounds as prenyl transferase inhibitors.
GI



I

AB Title compds. [I; X = (CHR11)n3(CH2)n4Z(CH2)n5; n3 = 0, 1; n4, n5 = 0-3; Z = O, NR12, S, bond; Y = CO, CH2, CS, bond; R1 = (substituted) imidazolyl, triazolyl, tetrazolyl, benzimidazolyl, isoquinolinyl, pyridyl, etc.; R3 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R4, R5 = H, (substituted) alkyl, cycloalkyl, aryl, heterocyclyl; R6 = H, (substituted) alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R7 = H, :O, :S, (substituted) alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; W = null, C], were prepared as prenyl transferase inhibitors (no data). Thus, 1-(2-ethoxy-2-oxoethyl)-2-[(1S)-[[(phenylmethoxy)carbonyl]amino]pentyl]-4-(2-methoxyphenyl)imidazole (preparation given) was hydrogenated in HOAc over Pd/C to give 8-butyl-6-oxo-2-(2-methoxyphenyl)imidazo[1,2-a]pyrazine. This was converted to 8-butyl-7-[3-(imidazol-5-yl)-1-oxopropyl]-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine in several steps.
AN 2000:457071 HCAPLUS <<LOGINID::20091229>>
DN 133:89553
TI Preparation of imidazopyrazines, imidazobenzodiazepines, and related compounds as prenyl transferase inhibitors.
IN Gordon, Thomas B.; Morgan, Barry A.
PA Societe de Conseils de Recherches et d'Applications Scientifiques S.A., Fr.
SO PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000039130	A2	20000706	WO 1999-US31302	19991230
	WO 2000039130	A3	20001102		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,

```
            MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
            SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
            DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
            CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2356756           A1    20000706    CA 1999-2356756        19991230
     EP 1140942           A2    20011010    EP 1999-968984         19991230
     EP 1140942           B1    20040310
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
     HU 2001004708        A2    20020429    HU 2001-4708           19991230
     HU 2001004708        A3    20040528
     EP 1382607           A2    20040121    EP 2003-78315          19991230
     EP 1382607           A3    20040630
     EP 1382607           B1    20090819
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, FI, CY
     AT 261447            T     20040315    AT 1999-968984         19991230
     PT 1140942           E     20040531    PT 1999-968984         19991230
     ES 2215420           T3    20041001    ES 1999-968984         19991230
     RU 2241712           C2    20041210    RU 2001-121317         19991230
     AT 440100            T     20090915    AT 2003-78315          19991230
     ES 2328564           T3    20091116    ES 2003-78315          19991230
     NO 2001003281        A     20010829    NO 2001-3281           20010629
     NO 321057            B1    20060306
     US 7084135           B1    20060801    US 2001-868356         20010810
     US 7361656           B2    20080422    US 2006-353518         20060214
     US 20060142275       A1    20060629
     US 20080176835       A1    20080724    US 2007-929118         20071030
PRAI US 1998-114301P      P     19981231
     US 1998-224428       A1    19981231
     EP 1999-968984       A3    19991230
     WO 1999-US31302      W     19991230
     US 2001-868356       A1    20010810
     US 2006-353518       A3    20060214
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS   MARPAT 133:89553
OSC.G   2     THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT  2     THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
```